RETROSPECTIVE AUDIT OF PATIENTS TREATED FOR MDR-TB IN RE-TREATMENT CATEGORY
Abstract
Objective: To determine the efficacy of our modified anti-tuberculosis regimen in adult patients withmulti-drug-resistant tuberculosis (MDR-TB) in the re-treatment category. Methods: Retrospective chartreview of 176 patients in re-treatment category with diagnosis of MDR-TB from 1st Jan 1993 to 31st Dec2002 managed at the Department of Pulmonology Military Hospital Rawalpindi, Pakistan. All the patientswere given four standard first line anti-TB drugs along with any two second line drugs out ofOfloxacin/Ciprofloxacin/Levofloxacin, Amikacin, or Clarithromycin and treatment was modified afteravailability of drug susceptibility testing (DST). Results: Seventy-two percent of the patients were youngmen with mean age of 32.28±8.7 yrs, 53.4% had moderately advanced while nearly 30% had extensivedisease. One-third cases had contact with a patient of pulmonary tuberculosis out of which one fifth hadcontact with a MDR-TB patient. Mean duration of diagnosis of tuberculosis before therapy was41.11±14.32 months and 70% of the cases had received at least 2 prior anti-TB regimens. They hadreceived a median of four anti-TB drugs in past and were infected with organisms that were resistant to amedian of 3 first line anti-TB drugs. Resistance to Ethambutol and PZA was about 18% and 11%respectively. A median of six anti-TB drugs was used while mean duration of therapy was 22.17±2.17months. Bacteriological cure was achieved in about 90% cases while radiological response wasdocumented in nearly 78%. Conclusion: Modified initial management strategy followed by DST guidedtherapy has yielded excellent results and needs to be assessed in further trials for wider application.Keywords: Modified regimen, Re-treatment TB, Multi-drug-resistant tuberculosis, MDR-TB, TuberculosisReferences
Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C.
Tuberculosis. Lancet 2003;362:887–99.
Schluger NW, Harkin TJ, Rom WN. Principles of therapy of
tuberculosis in the modern era. In: Rom WN & Garay S,
(Eds) Tuberculosis, 1st edn New York: Little Brown and
Company; 1996. p.751–61.
Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchenik
AE, Ashkin D. Treatment experience of Multi Drug
Resistance Tuberculosis in Florida, 1994-1997. Chest
;120:343–8.
Espinal MA. The global situation of MDR-TB. Tuberculosis
;83:44–51.
Bastain I, Colebunders R. Treatment and prevention of
multidrug resistant tuberculosis. Drugs1999;58(4):633–41.
World Health Organization. Anti-tuberculosis drug resistance
in the world. The WHO/IUATLD Global Project on AntiTuberculosis Drug Resistance Surveillance
(WHO/TB/97.229). Geneva, World Health Organization
Document, 1997.
World Health Organization. Anti-tuberculosis drug resistance
in the world. Third global report. The WHO/IUATLD Global
Project on Anti-Tuberculosis Drug Resistance Surveillance
(WHO/CDC/TB/2004). Geneva, World Health Organization
document, 2004.
Espinal MA, Kim SJ, Suárez PG, Kam KM, Khomenko AG,
Migliori GB, et al. Standard short-course chemotherapy for
drug-resistant tuberculosis: treatment outcomes in 6
countries. JAMA 2000;283:2537–45.
Kimerling ME, Kluge H, Vezhnina N, Iacovazzi
T, Demeulenaere T, Portaels F, et al. Inadequacy of the
current WHO re-treatment regimen in a central Siberian
prison: treatment failure and MDR-TB. Int J Tuberc Lung
Dis 1999;3:451–3.
Butt T, Ahmad R N, Kazmi S Y, Rafi N. Multi-drug resistant
Tuberculosis in Northern Pakistan. J Pak Med Assoc
;54:469–72.
Almani SA, Memon NM, Qureshi AF. Drug Resistant
Tuberculosis in Sindh. J Coll Physicians Surg Pak
;12(3):136–9.
Iseman MD. Mycobacterial Diseases of the Lungs. In:
Hanley ME, Welsh CH (Eds). Current Diagnosis &
Treatment in Pulmonary Medicine. New York: Lange
Medical Books/MaGraw Hill; 2003. p. 399–413.
Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L,
Horsburgh CR. Treatment of 171 patients with pulmonary
tuberculosis resistant to isoniazid and rifampin. N Engl J
Med 1993;328:527–32.
Chan ED, Laurel V, Strand MJ, Chan JF, Huynh MLN,
Goble M, et al. Treatment and Outcome Analysis of 205
Patients with Multidrug-resistant Tuberculosis. Am J Respir
Crit Care Med 2004;169:1103–9
Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara
F, et al. Community Based Therapy for Multi Drug Resistant
Tuberculosis in Lima, Peru. N Engl J Med 2003;348:119–28.
Suo J, Yu MC, Lee CN, Chiang CY, Lin TP. Treatment of
multi-drug resistant tuberculosis in Taiwan. Chemotherapy
;42(Suppl)3:20–3.
Park, SK, Kim CT, Song SD. Outcome of chemotherapy in
patients with pulmonary tuberculosis resistant to isoniazid
and rifampin. Int J Tuberc Lung Dis 1998;2:877–84.
Tahaoglu K, Torun T, Sevin T, Atac G, Kir A, Karasulu L,
Ozmen I, et al. The Treatment of Multidrug-Resistant
Tuberculosis in Turkey. N Engl J Med 2001;345:170–4.
Kim SJ. Drug susceptibility testing in tuberculosis: methods
and reliability of the results. Eur Respir J 2005;25:564–9.
Caminero JA. Management of multidrug-resistant
tuberculosis and patients in re-treatment. Eur Respir J
;25:928–36.
Ormerod LP. Multidrug resistant tuberculosis (MDR-TB):
epidemiology, prevention and treatment. Br Med Bull
;73–74:17–24.
Partners in Health Program in Infectious Disease and Social
Change, Harvard Medical School. The PIH Guide to the
Medical Management of Multi-Drug Resistant Tuberculosis.
Boston, MA. Partners in Health, 2003.
Pierri GD, Bonora S. Which agents should we use for the
treatment of multi-drug resistant Mycobacterium
tuberculosis? J Antimicrob Chemother 2004; 54:593–602.
Published
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
